Screener
Vaxcyte, Inc. PCVX Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:12 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001649094-26-000017
| Operating expenses: | | | | Research and development - external costs (1) | $256,432 | $103,806 | | Research and development - internal costs (2) | 56,347 | 44,328 | | General and administrative | 33,071 | 32,659 | | Total operating expenses | $345,850 | $180,793 | | Total other income, net | 25,228 | 40,075 | | Net loss | $320,622 | $140,718 |
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Vaxcyte, Inc.'s business segments — R&D?
- Vaxcyte, Inc. (PCVX) reported business segments — R&D of $256.43M in Q1 2026.
- How has Vaxcyte, Inc.'s business segments — R&D changed year-over-year?
- Vaxcyte, Inc.'s business segments — R&D increased by 147.0% year-over-year, from $103.81M to $256.43M.
- What is the long-term trend for Vaxcyte, Inc.'s business segments — R&D?
- Over 3 years (2022 to 2025), Vaxcyte, Inc.'s business segments — R&D has grown at a 65.5% compound annual growth rate (CAGR), from $132.42M to $600.69M.
- What does business segments — R&D mean?
- This metric represents the total expenditures incurred by the business segment for scientific research and the development of new product candidates. It reflects the company's commitment to innovation and the advancement of its clinical pipeline. High levels of investment in this area are critical for long-term growth in the biotechnology sector.
Ask your AI about Vaxcyte, Inc.'s business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude